Find Print
0 Find synonyms

Find synonyms Find exact match

What's new in allergy and immunology
UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2018 UpToDate, Inc. and/or its affiliates. All Rights Reserved.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2018 UpToDate, Inc.
What's new in allergy and immunology
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Dec 2017. | This topic last updated: Jan 05, 2018.

The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.

ASTHMA AND COPD

Tiotropium for severe symptomatic asthma in children (December 2017)

In a 12-week randomized trial in 400 children (aged 6 to 11 years) with severe symptomatic asthma, once-daily tiotropium 5 mcg, but not 2.5 mcg, improved lung function compared with placebo and was well tolerated as add-on therapy to inhaled glucocorticoids and other maintenance therapies [1]. However, consistent with studies in adults, no differences for placebo versus tiotropium at either dose were noted in patient-important outcomes such as asthma symptoms or rescue medication use. Although tiotropium 2.5 mcg/day is approved in the United States for maintenance treatment of asthma, further studies are needed to better define the role and optimal dosing of tiotropium for severe symptomatic asthma not well controlled on standard maintenance therapies. (See "Asthma in children younger than 12 years: Treatment of persistent asthma with controller medications", section on 'Tiotropium'.)

Exhaled nitric oxide analysis and chronic cough (October 2017)

An increase in the fraction of exhaled nitric oxide (FENO) is a marker of eosinophilic airway inflammation. A potential role for measuring FENO in the diagnosis of cough-variant asthma (associated with eosinophilic inflammation) and nonasthmatic eosinophilic bronchitis (NAEB) was examined in a systematic review of over 2000 patients, in which FENO performed better to "rule in" cough-variant asthma and NAEB (as determined by a response to inhaled corticosteroids) than to exclude them, and performance was better for patients with cough-variant asthma than chronic cough without asthma [2]. However, heterogeneity among studies was high, limiting the strength of the evidence. Further study is needed to clarify whether FENO measurement can help improve patient-important outcomes in chronic cough. (See "Exhaled nitric oxide analysis and applications", section on 'Cough variant asthma' and "Exhaled nitric oxide analysis and applications", section on 'Nonasthmatic eosinophilic bronchitis'.)

Global asthma mortality (October 2017)

Asthma ranks 32nd as a cause of death worldwide, but mortality varies among countries [3]. Based on World Health Organization (WHO) data, age-standardized death rates per 100,000 individuals aged 5 to 34 years range from 17.16 in India and 1.65 in China to 0.88 in the United States and 0.24 in the Netherlands. In an analysis of the WHO database, asthma mortality was essentially unchanged from 2006 to 2012, after decreasing substantially from 1993 to 2006 [4]. Lower mortality rates correlated with adoption of best practices and more widespread implementation of established asthma management strategies is needed. (See "Identifying patients at risk for fatal asthma", section on 'Mortality statistics'.)

Mepolizumab for eosinophilic granulomatosis with polyangiitis (August 2017)

Mepolizumab, a monoclonal anti-interleukin-5 antibody, is approved for use in severe eosinophilic asthma. In a multicenter trial, 136 patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) were randomly assigned to receive subcutaneous mepolizumab 300 mg or placebo every four weeks for 52 weeks [5]. Mepolizumab led to significantly more accrued weeks of remission and a lower frequency of relapse. Among mepolizumab-treated subjects, 44 percent were able to taper prednisolone to ≤4 mg/day, compared with 7 percent on placebo. While not all patients respond, high-dose mepolizumab may be an additional option for selected patients with EGPA. (See "Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)".)

DRUG HYPERSENSITIVITY

Cyclosporine for Stevens-Johnson syndrome/toxic epidermal necrolysis (November 2017)

Beyond supportive care, there are no established therapies for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), a severe and often life-threatening drug reaction. Immunosuppressive or immunomodulating therapies used in clinical practice include systemic corticosteroids, intravenous immune globulins, and cyclosporine. None has been adequately studied in randomized trials, but there is increasing evidence that cyclosporine may slow the progression of SJS/TEN. In a meta-analysis of observational studies including 134 patients with SJS/TEN treated with cyclosporine, the observed mortality rate was approximately 60 percent lower than that expected based upon the SCORTEN prognostic score at admission [6]. We suggest cyclosporine in addition to supportive care for the treatment of SJS/TEN. (See "Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae", section on 'Cyclosporine'.)

Identification of children with low-risk past penicillin reactions (August 2017)

Many children who have mild adverse reactions to penicillins, such as maculopapular rash, hives, or gastrointestinal symptoms, are not allergic and can safely receive this class of antibiotics in the future. In a study of children presenting to an urban emergency department with histories of past penicillin reactions, nearly 600 parents/caregivers completed a questionnaire about the child’s past reaction [7]. The questionnaire included hives as a low-risk feature (for true allergy), but considered facial angioedema as a high-risk feature. One hundred of 434 patients with low-risk reactions were referred to an allergist for evaluation. Ninety-seven had negative skin tests, while three initially had positive skin tests that were negative upon later repeat testing. Ultimately, all 100 children passed oral challenge to amoxicillin. Despite these results, we consider both hives and angioedema as high-risk features and would advocate that children with past reactions involving either of these symptoms be referred to an allergy specialist to determine if penicillins can be safely used again. (See "Penicillin allergy: Delayed hypersensitivity reactions", section on 'Studies in children'.)

FOOD ALLERGY AND INTOLERANCE

Multifood oral immunotherapy plus anti-IgE (December 2017)

Oral immunotherapy (OIT), an experimental treatment for food allergy, is being studied in combination with anti-immunoglobulin E (anti-IgE) in an attempt to decrease the serious side effects of OIT and enable more rapid desensitization. In one trial, 48 children aged 4 to 15 years with two to five food allergies were randomly assigned to pretreatment with omalizumab (anti-IgE) or placebo, followed by rush multifood OIT [8]. Compared with OIT alone, pretreatment with omalizumab resulted in a higher rate of desensitization to at least two offending foods and a lower rate of adverse events. These results suggest that the addition of anti-IgE to multifood OIT improves both efficacy and safety, but further trials are needed to clarify which patients would benefit most from this approach. (See "Investigational therapies for food allergy: Oral immunotherapy", section on 'OIT plus anti-IgE'.)

Peanut epicutaneous immunotherapy (December 2017)

Epicutaneous immunotherapy (EPIT) is an investigational approach for delivering immunotherapy that solubilizes the allergen by perspiration and delivers it into the skin. In an international trial comparing EPIT (50, 100, or 250 mcg) with placebo in patients 6 to 55 years of age with peanut allergy, all groups demonstrated some degree of treatment success, but the benefit compared with placebo was only significant for the 250 mcg dose [9]. The greatest effect was seen in children aged 6 to 11 years. Findings from this and an earlier trial support the effectiveness of EPIT, particularly in younger children. A phase 3 trial in children aged 4 to 11 years is underway. (See "Investigational therapies for food allergy: Immunotherapy and nonspecific therapies", section on 'Epicutaneous immunotherapy'.)

Data limited for probiotic plus oral immunotherapy for peanut allergy (August 2017)

Oral immunotherapy (OIT) for foods is an investigational treatment for food allergies that can lead to temporary desensitization to a food, but the ability of OIT to induce permanent tolerance to the food is less clear. Adding an immunostimulatory adjuvant, such as a probiotic, to OIT may improve sustained unresponsiveness (SU) to the food allergen. In a follow-up study four years after completion of a randomized trial and cessation of treatment, patients treated with peanut OIT plus probiotic were more likely to still be eating peanut and to have SU after eight weeks of avoidance compared with patients treated with placebo only [10]. However, there were significant flaws in the study design, and we await further data before recommending routine use of OIT (with or without an adjuvant). (See "Investigational therapies for food allergy: Oral immunotherapy", section on 'OIT plus adjuvant'.)

National Academies consensus report on food allergies (August 2017)

The National Academies of Sciences, Engineering, and Medicine consensus report on food allergies highlights a number of critical issues related to food allergy [11].

These include:

Judicious use of food allergy testing, performed and interpreted in the context of the patient's clinical history

Prompt treatment of anaphylaxis with epinephrine

Primary prevention of peanut allergy through early dietary introduction

Our approach to the diagnosis and management of food allergies is consistent with the recommendations in this report. (See "Diagnostic evaluation of food allergy", section on 'Role of allergy tests in diagnosis' and "Food-induced anaphylaxis", section on 'Epinephrine' and "Introducing highly allergenic foods to infants and children", section on 'Suggested approach'.)

Four-food elimination diet for eosinophilic esophagitis (July 2017)

The traditional six-food (cow's milk, hen's egg, soy, wheat, peanut/tree nuts, and fish/shellfish) elimination diet for eosinophilic esophagitis (EoE) results in resolution of EoE in approximately three-quarters of children but is challenging and can have negative nutritional consequences. In a prospective study of four-food elimination (milk, soy, egg, wheat) in 78 children with EoE, histologic remission was achieved in 64 percent, with decreased symptoms in 91 percent [12]. Thus, we now suggest either the four-food or six-food empiric elimination diet for most patients who opt for dietary management of EoE. (See "Dietary management of eosinophilic esophagitis", section on 'Elimination diets'.)

IMMUNODEFICIENCY

Consensus statement on granulomatous and lymphocytic interstitial lung disease (August 2017)

Granulomatous and lymphocytic interstitial lung disease (GLILD) is the most common cause of diffuse parenchymal lung disease in patients with common variable immunodeficiency, but the literature to date has been limited to case reports and small series. The British Lung Foundation and UK Primary Immunodeficiency Network published a consensus statement summarizing the experience of approximately 30 physicians caring for over 100 patients with GLILD [13]. It includes a proposed definition for the disorder, as well as several statements about diagnosis and first-line therapy, and is intended to provide preliminary guidance for care and future research. (See "Pulmonary complications of primary immunodeficiencies", section on 'Granulomatous and lymphocytic interstitial lung disease'.)

URTICARIA AND ANGIOEDEMA

Recombinant C1 inhibitor for prevention of hereditary angioedema attacks (October 2017)

Conestat alfa (Ruconest in the United States and Europe, Rhucin in other countries) is a recombinant human C1 inhibitor (rhC1INH) preparation that has been available for acute treatment of hereditary angioedema attacks. It has a much shorter half-life than plasma-derived C1INH, and its efficacy for prophylaxis had not been studied. A multicenter randomized trial of 26 patients with high attack rates demonstrated that rhC1INH given intravenously twice weekly resulted in a mean of 2.7 attacks per month, compared with 7.2 attacks with placebo [14]. The recombinant product has the advantages of a stable supply chain and no risk of transmission of bloodborne infections, compared with the plasma-derived product, but its shorter half-life may limit its prophylaxis effectiveness and it has not been approved for this indication. In most situations, plasma-derived C1INH is preferred for prophylaxis, although if not available, rhC1INH provides another option. (See "Hereditary angioedema: General care and long-term prophylaxis", section on 'Intravenous recombinant C1 inhibitor'.)

Mixed data regarding icatibant in ACE inhibitor-induced angioedema (August 2017)

Although the bradykinin receptor antagonist icatibant has proven efficacy in hereditary angioedema, particularly when given soon after onset of symptoms, evidence is mixed regarding its utility in angiotensin-converting enzyme inhibitor-associated angioedema (AceIA). In a randomized trial of 121 patients with AceIA of the head or neck, icatibant did not decrease the time to discharge relative to placebo [15]. Therefore, careful airway management, rather than icatibant, remains the primary intervention for most cases of AceIA, although icatibant may have a role in rare instances when patients present very early. (See "ACE inhibitor-induced angioedema", section on 'Icatibant'.)

New mutation in hereditary angioedema with normal C1 inhibitor (July 2017)

Most patients with hereditary angioedema have deficiency or dysfunction of C1 inhibitor, but a subset have no identifiable complement abnormalities. Within this subgroup, mutations in the gene for factor XII account for the disease in some families, while pathogenesis in the remainder has been unexplained. Now, a mutation has been identified in the gene encoding angiopoietin-1 (ANGPT1), a glycoprotein that inhibits bradykinin-induced plasma leakage, in one Italian family [16]. The mutation was present in four symptomatic women and absent in seven asymptomatic relatives. Understanding of the genetic basis of this disease is gradually expanding, and other mutations potentially leading to the hereditary angioedema phenotype will likely be found over time. (See "Hereditary angioedema with normal C1 inhibitor", section on 'Other mutations'.)

VACCINES AND VACCINE HYPERSENSITIVITY

Influenza vaccination in individuals with egg allergy (December 2017)

Numerous studies have demonstrated that egg-based influenza vaccines are safe in individuals with egg allergy, resolving longstanding concerns about an increased risk of allergic reactions to the vaccine in this population. Accordingly, the 2017 update of guidelines from the American Academy of Allergy, Asthma, and Immunology (AAAAI)/American College of Allergy, Asthma, and Immunology (ACAAI) Joint Task Force on Practice Parameters no longer recommends inquiring about egg allergy before influenza vaccine administration [17]. Individuals with egg allergy of any severity should undergo yearly influenza vaccination administered in the usual manner according to standard indications and contraindications, without special precautions. Our approach is consistent with these guidelines. (See "Influenza vaccination in individuals with egg allergy", section on 'Vaccine choice'.)

2017-2018 influenza immunization recommendations for the United States (September 2017)

The Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have released recommendations for influenza immunization for the 2017-2018 season in the United States [18,19]. Routine influenza immunization with a licensed, age-appropriate vaccine (table 1) is recommended for all persons ≥6 months of age. Live attenuated influenza vaccine is not recommended for the 2017-2018 season. Pregnant women and persons with egg allergy of any severity can receive any licensed, age-appropriate inactivated influenza vaccine with standard immunization precautions. Although neither the ACIP nor the AAP provide a preference for a particular formulation, we favor a quadrivalent vaccine when available for adults <65 years and we recommend the high-dose vaccine for those ≥65 years. (See "Seasonal influenza in children: Prevention with vaccines", section on 'Types of vaccine' and "Seasonal influenza vaccination in adults", section on 'Choice of vaccine formulation' and "Influenza and pregnancy", section on 'Vaccination' and "Influenza vaccination in individuals with egg allergy", section on 'Safety of vaccines in patients with egg allergy'.)

OTHER GENERAL ALLERGY AND IMMUNOLOGY

Probiotics ineffective for the prevention of early childhood eczema (October 2017)

Two meta-analyses in 2012 and 2014 suggested that there was a modest protective effect of probiotics used in late pregnancy/early infancy on the development of eczema within the first two years of life, although subsequent trials did not confirm these findings. A recent randomized trial provides further evidence of the lack of effectiveness of probiotics for eczema prevention [20]. In this trial, 184 high-risk infants received either Lactobacillus rhamnosus GG plus inulin or inulin alone for the first six months of life. Eczema was diagnosed by age two in approximately 30 percent of the children in both groups. We suggest not giving probiotics during pregnancy and infancy for the prevention of eczema. (See "Prebiotics and probiotics for prevention of allergic disease", section on 'Efficacy'.)

Midostaurin for advanced systemic mastocytosis (August 2017)

Cytoreductive treatment of advanced systemic mastocytosis (SM) can mitigate organ dysfunction, improve quality of life, and limit disease progression until a suitable donor for allogeneic hematopoietic cell transplant is identified. Midostaurin is a multikinase inhibitor that is effective against SM with wild type or mutant KIT (eg, KIT D816V). A recent phase II study found that midostaurin was associated with improved measures of organ damage (eg, cytopenias, liver function studies) in two-thirds of patients with advanced SM, with median overall survival >3 years [21], confirming similar findings from an earlier trial [22]. The drug was well tolerated, with primarily grade 1 to 2 nausea/vomiting or modest cytopenias. The US Food and Drug Administration approved midostaurin for treatment of advanced SM earlier this year. We now suggest midostaurin for initial systemic therapy of advanced SM. (See "Systemic mastocytosis: Management and prognosis", section on 'Choice of therapy'.)

Use of UpToDate is subject to the  Subscription and License Agreement.

REFERENCES

  1. Szefler SJ, Murphy K, Harper T 3rd, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol 2017.
  2. Song WJ, Kim HJ, Shim JS, et al. Diagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough: A systematic review and meta-analysis. J Allergy Clin Immunol 2017; 140:701.
  3. www.worldlifeexpectancy.com/cause-of-death/asthma/by-country (Accessed on September 22, 2017).
  4. Ebmeier S, Thayabaran D, Braithwaite I, et al. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). Lancet 2017; 390:935.
  5. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 2017; 376:1921.
  6. González-Herrada C, Rodríguez-Martín S, Cachafeiro L, et al. Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. J Invest Dermatol 2017; 137:2092.
  7. Vyles D, Adams J, Chiu A, et al. Allergy Testing in Children With Low-Risk Penicillin Allergy Symptoms. Pediatrics 2017; 140.
  8. Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 2017.
  9. Sampson HA, Shreffler WG, Yang WH, et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA 2017; 318:1798.
  10. Hsiao K-C, Ponsonby A-L, Axelrad C, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. The Lancet Child & Adolescent Health 2017.
  11. Sicherer SH, Allen K, Lack G, et al. Critical Issues in Food Allergy: A National Academies Consensus Report. Pediatrics 2017.
  12. Kagalwalla AF, Wechsler JB, Amsden K, et al. Efficacy of a 4-Food Elimination Diet for Children With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2017; 15:1698.
  13. Hurst JR, Verma N, Lowe D, et al. British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract 2017; 5:938.
  14. Riedl MA, Grivcheva-Panovska V, Moldovan D, et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet 2017; 390:1595.
  15. Sinert R, Levy P, Bernstein JA, et al. Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema. J Allergy Clin Immunol Pract 2017; 5:1402.
  16. Bafunno V, Firinu D, D'Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2017.
  17. Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017. Ann Allergy Asthma Immunol 2018; 120:49.
  18. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. MMWR Recomm Rep 2017; 66:1.
  19. COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018. Pediatrics 2017; 140.
  20. Cabana MD, McKean M, Caughey AB, et al. Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial. Pediatrics 2017; 140.
  21. DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia 2017.
  22. Chandesris MO, Damaj G, Canioni D, et al. Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med 2016; 374:2605.
Topic 8363 Version 7688.0

Topic Outline

GRAPHICS

RELATED TOPICS

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.